http://orcid.org/0000-0002-9188-4379
References
- Shi Y, Lan F, Matson C, Mulligan P, Whetstine JR, Pa C, Ra C, Shi Y. Histone demethylation mediated by the nuclear amine oxidase homolog LSD1. Cell. 2004;119:941–953. PMID:15620353 doi:10.1016/j.cell.2004.12.012.
- Maiques-Diaz A, Somervaille TC. LSD1: biologic roles and therapeutic targeting. Epigenomics. 2016;8:1103–1116. PMID: 27479862 doi:10.2217/epi-2016-0009.
- Mohammad HP, Smitherman KN, Kamat CD, Soong D, Federowicz KE, Van Aller GS, Schneck JL, Carson KD, Liu Y, Butticello M, et al.. A DNA hypomethylation signature predicts antitumor activity of LSD1 inhibitors in SCLC. Cancer Cell. 2015;28:57–69. PMID:26175415 doi:10.1016/j.ccell.2015.06.002.
- Harris WJ, Huang X, Lynch JT, Spencer GJ, Hitchin JR, Li Y, Ciceri F, Blaser JG, Greystoke BF, Jordan AM, et al.. The histone demethylase KDM1A sustains the oncogenic potential of MLL-AF9 leukemia stem cells. Cancer Cell. 2012;21:473–487. PMID: 22464800 doi:10.1016/j.ccr.2012.03.014.
- Somervaille TC, Salamero O, Montesinos P, Willekens C, Perez Simon J, Pigneux A, Recher C, Popat R, Molinero C, Mascaro C, et al.. Safety, pharmacokinetics (PK), pharmacodynamics (PD) and premliminary activity in acute leukemia of Ory-1001, a first-in-class inhibitor of lysine specific demethylase 1A (LSD1/KDM1A): initial results from a first-in-human phase 1 study. Blood. 2016;128:4026. Paper presented at the 58th Annual Meeting of the American Hematology Association doi:10.1182/blood-2016-06-724161.
- Maes T, Mascaro C, Tirapu I, Estiarte A, Ciceri F, Lunardi S, Guibourt N, Perdones A, Lufino MMP, Somervaille TCP, et al.. ORY-1001, a potent and selective covalent KDM1A inhibitor, for the treatment of acute leukemia. Cancer Cell. 2018;33(3):495–511. PMID: 29502954 doi:10.1016/j.ccell.2018.02.002.
- Maiques-Diaz A, Spencer GJ, Lynch JT, Ciceri F, Williams EL, Amaral FMR, Wiseman DH, Harris WJ, Li Y, Sahoo S, et al.. Enhancer activation by pharmacological displacement of LSD1 from GFI1 induces differentiation in acute myeloid leukemia. Cell Rep. 2018;22:3641–3659. PMID:29590629 doi:10.1016/j.celrep.2018.03.012.
- Saleque S, Kim J, Rooke HM, Orkin SH. Epigenetic regulation of hematopoietic differentiation by Gfi-1 and Gfi-1b is mediated by the cofactors CoREST and LSD1. Mol Cell. 2007;27:562–572. PMID:17707228 doi:10.1016/j.molcel.2007.06.039.
- Cusan M, Cai SF, Mohammad HP, Krivtsov A, Chramiec A, Loizou E, Witkin MD, Smitheman KN, Tenen DG, Ye M, et al.. LSD1 inhibition experts it anti-leukemic effect by recommissioning PU.1- and C/EBPA-dependent enhancers in AML. Blood. 2018;February 16 published online doi:10.1182/blood-2017-09-807024.